Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.
The role of insulin sensitizing agents is discussed at length in this Committee Opinion.
D004351:Drug Resistance / Q000187:drug effects*; D005260:Female; D005951:Glucose Tolerance Test; D006287:Health Planning Guidelines; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology; D008687:Metformin / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use; D010062:Ovulation Induction / Q000379:methods; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D045162:Thiazolidinediones / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D008687:Metformin; D015282:Octreotide